Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
Authors' conclusion
Since FFM contains a variable amount of muscle (approximately 55%), this indirect measure may explain the heterogeneity in the data.
Study context
- Population
- Clinical trials of GLP-1 RA-based agents (exenatide, liraglutide, semaglutide, tirzepatide) reporting DXA-measured changes in fat-free mass (FFM)28 clinical trials
- Outcome
- Percentage of weight lost as fat-free mass (%FFML = ΔFFM/total weight change), DXA
Methodological detailsLimited to small substudies and DXA, which does not measure skeletal muscle mass directly
- Limited to small substudies and DXA, which does not measure skeletal muscle mass directly
Main finding
As reported in the abstract
%FFML with GLP-1 RA-based agents
%FFML using GLP-1 RA-based agents
between 20% and 40%
Original publication
Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps. Diabetes Obes Metab. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →